Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma

Oncogene

Volumn 26, Issue 25, 2007, Pages 3699-3703

  Waldmann, T A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adult T cell leukemia; Anti Tac; IL 2 receptor; Monoclonal antibody

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; DACLIZUMAB; DACLIZUMAB Y 90 CONJUGATE; FLAVOPIRIDOL; INTERLEUKIN 2 RECEPTOR ALPHA; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG APPROVAL; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; INFLAMMATORY DISEASE; KIDNEY GRAFT REJECTION; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUKEMIA; LYMPHOMA; RADIOISOTOPES;

EID: 34249734842     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210368     Document Type: Review

References (42)

1. Beniaminovitz A, Itescu S, Lietz K, Donovan M, Burke EM, Groff BD et al. (2000). Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 342: 613-619.
2. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA et al. (2006). Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiplescle rosis. Proc Natl Acad Sci USA 103: 5941-5946.
3. Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J et al. (2004). Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 101: 8705-8708.
4. Depper JM, Leonard WJ, Kronke M, Noguchi PD, Cunningham RE, Waldmann TA et al. (1984). Regulation of interleukin 2 receptor expression: effects of phorbol diester, phospholipase C, and reexposure to lectin or antigen. J Immunol 133: 3054-3061.
5. Eckhoff DE, McGuire B, Sellers M, Contreras J, Frenette L, Young C et al. (2000). The safety and efficacy of a two-dose daclizumab (Zenapax) induction therapy in liver transplant recipients. Transplantation 69: 1867-1872.
6. Jeang KT. (2001). Functional activities of the human T-cell leukemia virus type I Tax oncoprotein: cellular signaling through NF-kappa B. Cytokine Growth Factor Rev 12: 207-217.
7. Junghans RP, Waldmann TA, Landolfi NF, Avdalovic NM, Schneider WP, Queen C. (1990). Anti-Tac-H a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res 50: 1495-1502.
8. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, JaffeES, Giardina S et al. (2000). PhaseI trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18: 1622-1636.
9. Krueger JG, Walters IB, Miyazawa M, Gilleaudeau P, Hakimi J, Light S et al. (2000). Successful in vivo blockade of CD25 (high-affinity interleukin-2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 43: 448-458.
10. Lehky TJ, Levin MC, Kubota R, Bamford RN, Flerlage AN, Soldan SS et al. (1998). Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac. Ann Neurol 44: 942-947.
11. Leonard WJ, Depper JM, Crabtree GR, Rudikoff S, Pumphrey J, Robb RJ et al. (1984). Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature 311: 626-631.
12. Leonard WJ, Depper JM, Kronke M, Robb RJ, Waldmann TA, Greene WC. (1985). The human receptor for T-cell growth factor. Evidence for variable post-translational processing phosphorylation sulfation and the ability of precursor forms of the receptor to bind T-cell growth factor. J Biol Chem 260: 1872-1880.
13. Leonard WJ, Depper JM, Uchiyama T, Smith KA, Waldmann TA, Greene WC. (1982). A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor: partial characterization of the receptor. Nature 300: 267-269.
14. Li Z, Lim WK, Mahesh SP, Liu B, Nussenblatt RB. (2005). Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J Immunol 174: 5187-5191.
15. Maciejewski JP, Sloand EM, Nunez O, Boss C, Young NS. (2003). Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia. Blood 102: 3584-3586.
16. Morris JC, Waldmann TA. (2000). Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis 59(Suppl 1): i109-i114.
17. Nashan B, Light S, HardieIR, Lin A, Johnson JR. (1999). Reduction of acute renal allograft rejection by daclizumab. Daclizumab DoubleThe rapy Study Group. Transplantation 67: 110-115.
18. Nussenblatt RB, Fortin E, Schiffman R, Rizzo L, Smith J, Van VP et al. (1999). Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phaseI/II clinical trial. Proc Natl Acad Sci USA 96: 7462-7466.
19. O'Mahony D, Morris JC, Carrasquillo JA, LeN, Paik CH, Whatley M et al. (2006). PhaseI/II study of Yttrium-90 labeled humanized anti-Tac (HAT) monoclonal antibody and calcium DTPA in CD25-expressing malignancies. J Nucl Med 47: 98P.
20. Phillips KE, Herring B, Wilson LA, Rickford MS, Zhang M, Goldman CK et al. (2000). IL-2R alpha directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockadeof IL-2/IL-2R alpha interaction. Cancer Res 60: 6977-6984.
21. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF et al. (1989). A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 86: 10029-10033.
22. Rubin LA, Nelson DL. (1990). The soluble interleukin-2 receptor: biology function and clinical application. Ann Intern Med 113: 619-627.
23. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL et al. (2000). Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343: 230-238.
24. Sharon M, Klausner RD, Cullen BR, Chizzonite R, Leonard WJ. (1986). Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions. Science 234: 859-863.
25. Sloand EM, Scheinberg P, Maciejewski J, Young NS. (2006). Brief communication: successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (daclizumab). Ann Intern Med 144: 181-185.
26. Sugamura K, Asao H, Kondo M, Tanaka N, Ishii N, Ohbo K et al. (1996). The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Annu Rev Immunol 14: 179-205.
27. Tan C, Waldmann TA. (2002). Proteasome inhibitor PS-341 a potential therapeutic agent for adult T-cell leukemia. Cancer Res 62: 1083-1086.
28. Tsudo M, Kozak RW, Goldman CK, Waldmann TA. (1986). Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex. Proc Natl Acad Sci USA 83: 9694-9698.
29. Uchiyama T, Broder S, Waldmann TA. (1981a). A monoclonal antibody (anti-Tac) reactive with activated and functionally maturehuman T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol 126: 1393-1397.
30. Uchiyama T, Nelson DL, Fleisher TA, Waldmann TA. (1981b). A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells II. Expression of Tac antigen on activated cytotoxic killer T cells suppressor cells and on one of two types of helper T cells. J Immunol 126: 1398-1403.
31. Uchiyama T, Yodoi J, Sagawa K, Takatuski K, Uchino H. (1977). Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 50: 481-492.
32. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P et al. (1998). Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation: daclizumab triplethe rapy study group. N Eng J Med 338: 161-165.
33. Waldmann TA. (1986). The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 232: 727-732.
34. Waldmann TA. (1989). The multi-subunit interleukin-2 receptor. Annu Rev Biochem 58: 875-911.
35. Waldmann TA. (2003). The meandering 45-year odyssey of a clinical immunologist. Annu Rev Immunol 21: 1-27.
36. Waldmann TA, Goldman CK, Bongiovanni KF, Sharrow SO, Davey MP, Cease KB et al. (1988). Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac a monoclonal antibody to the receptor for interleukin-2. Blood 72: 1805-1816.
37. Waldmann TA, WhiteJD, Carrasquillo JA, Reynolds JC, Paik CH, Gansow OA et al. (1995). Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood 86: 4063-4075.
38. Waldmann TA, WhiteJD, Goldman CK, Top L, Grant A, Bamford R et al. (1993). The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotropic virus I-induced adult T-cell leukemia. Blood 82: 1701-1712.
39. Wiseman LR, Faulds D. (1999). Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients. Drugs 58: 1029-1042.
40. Zhang M, Yao Z, Zhang Z, Garmestani K, Talanov VS, Plascjak PS et al. (2006). Theanti-CD25 monoclonal antibody 7G7/B6, armed with the {alpha}-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia. Cancer Res 66: 8227-8232.
41. Zhang M, Zhang Z, Garmestani K, Goldman CK, Ravetch JV, Brechbiel MW et al. (2004). Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult T-cell leukemia. Cancer Res 64: 5825-5829.
42. Zhang M, Zhang Z, Goldman CK, Janik J, Waldmann TA. (2005). Combination of therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody. Blood 105: 1231-1236.